{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T17:31:20Z","timestamp":1773509480730,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2020,12,26]],"date-time":"2020-12-26T00:00:00Z","timestamp":1608940800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,12,26]],"date-time":"2020-12-26T00:00:00Z","timestamp":1608940800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003793","name":"Hj\u00e4rt-Lungfonden","doi-asserted-by":"publisher","award":["20160787"],"award-info":[{"award-number":["20160787"]}],"id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Hereditary transthyretin-amyloid amyloidosis (ATTRv) is an underdiagnosed condition commonly manifesting as congestive heart failure. Recently, scintigraphy utilizing DPD as a tracer was shown to identify ATTRv and wild-type ATTR cardiomyopathy. The aim of this study was to determine the value of quantified scintigraphy utilizing <jats:sup>99m<\/jats:sup>Tc-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) single-photon emission computed tomography (SPECT)\/CT, and to correlate its uptake with well-established cardiac functional parameters.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Forty-eight patients with genetically verified ATTRv type-A fibril composition, positive <jats:sup>99m<\/jats:sup>Tc-DPD SPECT\/CT, were retrospectively analyzed. Manual mapping of volumes of interest (VOIs) on DPD SPECT\/CT examinations was used to quantify heart uptake. DPD mean and maximum uptake together with a calculated DPD-based amyloid burden (DPD<jats:sub>load<\/jats:sub>) was correlated with echocardiographic strain values and cardiac biomarkers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Statistically significant correlations were seen in VOIs between DPD uptakes and the corresponding echocardiographic strain values. Furthermore, DPD<jats:sub>load<\/jats:sub> had a strong correlation with echocardiographic strain parameters and also correlated with biomarkers troponin T and logarithmic NT-ProBNP.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>In patients with ATTRv cardiomyopathy, DPD SPECT\/CT measures the amyloid distribution and provides information on cardiac amyloid load. DPD amyloid load correlates with functional cardiac parameters.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00259-020-05144-8","type":"journal-article","created":{"date-parts":[[2020,12,26]],"date-time":"2020-12-26T06:02:37Z","timestamp":1608962557000},"page":"1822-1832","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Cardiac transthyretin amyloidosis 99mTc-DPD SPECT correlates with strain echocardiography and biomarkers"],"prefix":"10.1007","volume":"48","author":[{"given":"Viktor","family":"L\u00f6fbacka","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Axelsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f6rn","family":"Pilebro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ole B.","family":"Suhr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Per","family":"Lindqvist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9071-8993","authenticated-orcid":false,"given":"Torbj\u00f6rn","family":"Sundstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,12,26]]},"reference":[{"issue":"6","key":"5144_CR1","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1056\/NEJMra023144","volume":"349","author":"G Merlini","year":"2003","unstructured":"Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med. 2003;349(6):583\u201396. https:\/\/doi.org\/10.1056\/NEJMra023144.","journal-title":"N Engl J Med"},{"issue":"2","key":"5144_CR2","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1046\/j.1365-2796.2003.01262.x","volume":"255","author":"G Merlini","year":"2004","unstructured":"Merlini G, Westermark P. The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies. J Intern Med. 2004;255(2):159\u201378.","journal-title":"J Intern Med"},{"issue":"4","key":"5144_CR3","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.pcad.2009.11.007","volume":"52","author":"RH Falk","year":"2010","unstructured":"Falk RH, Dubrey SW. Amyloid heart disease. Prog Cardiovasc Dis. 2010;52(4):347\u201361. https:\/\/doi.org\/10.1016\/j.pcad.2009.11.007.","journal-title":"Prog Cardiovasc Dis"},{"issue":"3","key":"5144_CR4","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1080\/07853890701842988","volume":"40","author":"M Tanskanen","year":"2008","unstructured":"Tanskanen M, Peuralinna T, Polvikoski T, Notkola IL, Sulkava R, Hardy J, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med. 2008;40(3):232\u20139. https:\/\/doi.org\/10.1080\/07853890701842988.","journal-title":"Ann Med"},{"issue":"38","key":"5144_CR5","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","volume":"36","author":"E Gonzalez-Lopez","year":"2015","unstructured":"Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, de Haro-Del Moral FJ, Cobo-Marcos M, Robles C, et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2585\u201394. https:\/\/doi.org\/10.1093\/eurheartj\/ehv338.","journal-title":"Eur Heart J"},{"issue":"6","key":"5144_CR6","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1016\/j.carpath.2015.07.008","volume":"24","author":"JJ Maleszewski","year":"2015","unstructured":"Maleszewski JJ. Cardiac amyloidosis: pathology, nomenclature, and typing. Cardiovasc Pathol. 2015;24(6):343\u201350. https:\/\/doi.org\/10.1016\/j.carpath.2015.07.008.","journal-title":"Cardiovasc Pathol"},{"issue":"13","key":"5144_CR7","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1161\/circulationaha.104.489187","volume":"112","author":"RH Falk","year":"2005","unstructured":"Falk RH. Diagnosis and management of the cardiac amyloidoses. Circulation. 2005;112(13):2047\u201360. https:\/\/doi.org\/10.1161\/circulationaha.104.489187.","journal-title":"Circulation"},{"issue":"sup1","key":"5144_CR8","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1080\/13506129.2016.1272453","volume":"24","author":"F Aus dem Siepen","year":"2017","unstructured":"Aus dem Siepen F, Hein S, Bauer R, Katus HA, Kristen AV. Standard heart failure medication in cardiac transthyretin amyloidosis: useful or harmful? Amyloid. 2017;24(sup1):132\u20133. https:\/\/doi.org\/10.1080\/13506129.2016.1272453.","journal-title":"Amyloid"},{"issue":"2","key":"5144_CR9","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s11897-006-0004-z","volume":"3","author":"DB Sawyer","year":"2006","unstructured":"Sawyer DB, Skinner M. Cardiac amyloidosis: shifting our impressions to hopeful. Curr Heart Fail Rep. 2006;3(2):64\u201371. https:\/\/doi.org\/10.1007\/s11897-006-0004-z.","journal-title":"Curr Heart Fail Rep"},{"issue":"3","key":"5144_CR10","doi-asserted-by":"publisher","first-page":"H544","DOI":"10.1152\/ajpheart.00815.2011","volume":"302","author":"J Guan","year":"2012","unstructured":"Guan J, Mishra S, Falk RH, Liao R. Current perspectives on cardiac amyloidosis. Am J Physiol Heart Circ Physiol. 2012;302(3):H544\u201352. https:\/\/doi.org\/10.1152\/ajpheart.00815.2011.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"1","key":"5144_CR11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, et al. Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med. 2018;379(1):22\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1716793.","journal-title":"N Engl J Med"},{"key":"5144_CR12","doi-asserted-by":"publisher","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, Elliott PM, Merlini G, Waddington-Cruz M, et al. Tafamidis Treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018. https:\/\/doi.org\/10.1056\/NEJMoa1805689.","DOI":"10.1056\/NEJMoa1805689"},{"issue":"12","key":"5144_CR13","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1016\/j.amjmed.2015.05.039","volume":"128","author":"MS Maurer","year":"2015","unstructured":"Maurer MS. Noninvasive identification of ATTRwt cardiac amyloid: the re-emergence of nuclear cardiology. Am J Med. 2015;128(12):1275\u201380. https:\/\/doi.org\/10.1016\/j.amjmed.2015.05.039.","journal-title":"Am J Med"},{"issue":"1","key":"5144_CR14","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s12350-013-9803-2","volume":"21","author":"S Bokhari","year":"2014","unstructured":"Bokhari S, Shahzad R, Castano A, Maurer MS. Nuclear imaging modalities for cardiac amyloidosis. J Nucl Cardiol. 2014;21(1):175\u201384. https:\/\/doi.org\/10.1007\/s12350-013-9803-2.","journal-title":"J Nucl Cardiol"},{"issue":"11","key":"5144_CR15","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.cardfail.2019.08.001","volume":"25","author":"S Dorbala","year":"2019","unstructured":"Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging. J Card Fail. 2019;25(11):e1\u2013e39. https:\/\/doi.org\/10.1016\/j.cardfail.2019.08.001.","journal-title":"J Card Fail"},{"issue":"1","key":"5144_CR16","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3109\/03009734.2015.1122687","volume":"121","author":"B Pilebro","year":"2016","unstructured":"Pilebro B, Suhr OB, Naslund U, Westermark P, Lindqvist P, Sundstrom T. (99m)Tc-DPD uptake reflects amyloid fibril composition in hereditary transthyretin amyloidosis. Ups J Med Sci. 2016;121(1):17\u201324. https:\/\/doi.org\/10.3109\/03009734.2015.1122687.","journal-title":"Ups J Med Sci"},{"issue":"2","key":"5144_CR17","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1002\/path.2411","volume":"216","author":"E Ihse","year":"2008","unstructured":"Ihse E, Ybo A, Suhr O, Lindqvist P, Backman C, Westermark P. Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis. J Pathol. 2008;216(2):253\u201361. https:\/\/doi.org\/10.1002\/path.2411.","journal-title":"J Pathol"},{"issue":"Suppl 1","key":"5144_CR18","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1080\/13506129.2003.12088568","volume":"10","author":"P Westermark","year":"2003","unstructured":"Westermark P, Bergstrom J, Solomon A, Murphy C, Sletten K. Transthyretin-derived senile systemic amyloidosis: clinicopathologic and structural considerations. Amyloid. 2003;10(Suppl 1):48\u201354.","journal-title":"Amyloid"},{"issue":"6","key":"5144_CR19","doi-asserted-by":"publisher","first-page":"1076","DOI":"10.1016\/j.jacc.2005.05.073","volume":"46","author":"E Perugini","year":"2005","unstructured":"Perugini E, Guidalotti PL, Salvi F, Cooke RM, Pettinato C, Riva L, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol. 2005;46(6):1076\u201384. https:\/\/doi.org\/10.1016\/j.jacc.2005.05.073.","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"5144_CR20","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1093\/ehjci\/jew325","volume":"18","author":"DF Hutt","year":"2017","unstructured":"Hutt DF, Fontana M, Burniston M, Quigley AM, Petrie A, Ross JC, et al. Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid. Eur Heart J Cardiovasc Imaging. 2017;18(12):1344\u201350. https:\/\/doi.org\/10.1093\/ehjci\/jew325.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"3","key":"5144_CR21","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1007\/s00259-010-1642-7","volume":"38","author":"C Rapezzi","year":"2011","unstructured":"Rapezzi C, Quarta CC, Guidalotti PL, Longhi S, Pettinato C, Leone O, et al. Usefulness and limitations of 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur J Nucl Med Mol Imaging. 2011;38(3):470\u20138. https:\/\/doi.org\/10.1007\/s00259-010-1642-7.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"11","key":"5144_CR22","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.hlc.2016.12.017","volume":"26","author":"PT Moore","year":"2017","unstructured":"Moore PT, Burrage MK, Mackenzie E, Law WP, Korczyk D, Mollee P. The utility of (99m)Tc-DPD scintigraphy in the diagnosis of cardiac amyloidosis: an Australian experience. Heart Lung Circ. 2017;26(11):1183\u201390. https:\/\/doi.org\/10.1016\/j.hlc.2016.12.017.","journal-title":"Heart Lung Circ"},{"issue":"5","key":"5144_CR23","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.jcmg.2014.03.002","volume":"7","author":"AV Kristen","year":"2014","unstructured":"Kristen AV, Scherer K, Buss S. aus dem Siepen F, Haufe S, Bauer R, Hinderhofer K, Giannitsis E, Hardt S, Haberkorn U, Katus HA, Steen H. Noninvasive risk stratification of patients with transthyretin amyloidosis. JACC Cardiovasc Imaging. 2014;7(5):502\u201310. https:\/\/doi.org\/10.1016\/j.jcmg.2014.03.002.","journal-title":"JACC Cardiovasc Imaging"},{"key":"5144_CR24","doi-asserted-by":"publisher","unstructured":"Ramsay SC, Cuscaden C. The current status of quantitative SPECT\/CT in the assessment of transthyretin cardiac amyloidosis. J Nucl Cardiol. 2019. https:\/\/doi.org\/10.1007\/s12350-019-01935-1.","DOI":"10.1007\/s12350-019-01935-1"},{"key":"5144_CR25","doi-asserted-by":"publisher","unstructured":"Caobelli F, Braun M, Haaf P, Wild D, Zellweger MJ. Quantitative 99m Tc-DPD SPECT\/CT in patients with suspected ATTR cardiac amyloidosis: feasibility and correlation with visual scores. J Nucl Cardiol. 2019. https:\/\/doi.org\/10.1007\/s12350-019-01893-8.","DOI":"10.1007\/s12350-019-01893-8"},{"issue":"3","key":"5144_CR26","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1080\/13506129.2018.1520087","volume":"25","author":"JC Ross","year":"2018","unstructured":"Ross JC, Hutt DF, Burniston M, Page J, Steeden JA, Gillmore JD, et al. Quantitation of 99mTc-DPD uptake in patients with transthyretin-related cardiac amyloidosis. Amyloid. 2018;25(3):203\u201310. https:\/\/doi.org\/10.1080\/13506129.2018.1520087.","journal-title":"Amyloid"},{"issue":"6","key":"5144_CR27","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/j.jcmg.2020.03.020","volume":"13","author":"PR Scully","year":"2020","unstructured":"Scully PR, Morris E, Patel KP, Treibel TA, Burniston M, Klotz E, et al. DPD quantification in cardiac amyloidosis: a novel imaging biomarker. JACC Cardiovasc Imaging. 2020;13(6):1353\u201363. https:\/\/doi.org\/10.1016\/j.jcmg.2020.03.020.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"1","key":"5144_CR28","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s40658-019-0268-5","volume":"6","author":"SMB Peters","year":"2019","unstructured":"Peters SMB, van der Werf NR, Segbers M, van Velden FHP, Wierts R, Blokland KJAK, et al. Towards standardization of absolute SPECT\/CT quantification: a multi-center and multi-vendor phantom study. EJNMMI Phys. 2019;6(1):29. https:\/\/doi.org\/10.1186\/s40658-019-0268-5.","journal-title":"EJNMMI Phys"},{"issue":"1","key":"5144_CR29","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13550-019-0475-z","volume":"9","author":"S Arvola","year":"2019","unstructured":"Arvola S, Jambor I, Kuisma A, Kemppainen J, Kajander S, Sepp\u00e4nen M, et al. Comparison of standardized uptake values between. EJNMMI Res. 2019;9(1):6. https:\/\/doi.org\/10.1186\/s13550-019-0475-z.","journal-title":"EJNMMI Res"},{"issue":"4","key":"5144_CR30","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.jcmg.2019.10.011","volume":"13","author":"M Boldrini","year":"2020","unstructured":"Boldrini M, Cappelli F, Chacko L, Restrepo-Cordoba MA, Lopez-Sainz A, Giannoni A, et al. Multiparametric echocardiography scores for the diagnosis of cardiac amyloidosis. JACC Cardiovasc Imaging. 2020;13(4):909\u201320. https:\/\/doi.org\/10.1016\/j.jcmg.2019.10.011.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"2","key":"5144_CR31","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1016\/j.jcmg.2015.05.014","volume":"9","author":"J Ternacle","year":"2016","unstructured":"Ternacle J, Bodez D, Guellich A, Audureau E, Rappeneau S, Lim P, et al. Causes and consequences of longitudinal LV dysfunction assessed by 2D strain echocardiography in cardiac amyloidosis. JACC Cardiovasc Imaging. 2016;9(2):126\u201338. https:\/\/doi.org\/10.1016\/j.jcmg.2015.05.014.","journal-title":"JACC Cardiovasc Imaging"},{"issue":"3","key":"5144_CR32","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1080\/13506129.2016.1194264","volume":"23","author":"D Bodez","year":"2016","unstructured":"Bodez D, Ternacle J, Guellich A, Galat A, Lim P, Radu C, et al. Prognostic value of right ventricular systolic function in cardiac amyloidosis. Amyloid. 2016;23(3):158\u201367. https:\/\/doi.org\/10.1080\/13506129.2016.1194264.","journal-title":"Amyloid"},{"issue":"11","key":"5144_CR33","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.jchf.2018.05.022","volume":"6","author":"M Amsallem","year":"2018","unstructured":"Amsallem M, Mercier O, Kobayashi Y, Moneghetti K, Haddad F. Forgotten no more: a focused update on the right ventricle in cardiovascular disease. JACC Heart Fail. 2018;6(11):891\u2013903. https:\/\/doi.org\/10.1016\/j.jchf.2018.05.022.","journal-title":"JACC Heart Fail"},{"issue":"4","key":"5144_CR34","doi-asserted-by":"publisher","first-page":"291","DOI":"10.5582\/irdr.2017.01065","volume":"6","author":"AM Kollikowski","year":"2017","unstructured":"Kollikowski AM, Kahles F, Kintsler S, Hamada S, Reith S, Kn\u00fcchel R, et al. In vivo quantification of amyloid burden in TTR-related cardiac amyloidosis. Intractable Rare Dis Res. 2017;6(4):291\u20134. https:\/\/doi.org\/10.5582\/irdr.2017.01065.","journal-title":"Intractable Rare Dis Res"},{"issue":"4","key":"5144_CR35","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1161\/circulationaha.118.035831","volume":"139","author":"SD Solomon","year":"2019","unstructured":"Solomon SD, Adams D, Kristen A, Grogan M, Gonz\u00e1lez-Duarte A, Maurer MS, et al. Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation. 2019;139(4):431\u201343. https:\/\/doi.org\/10.1161\/circulationaha.118.035831.","journal-title":"Circulation"},{"issue":"2","key":"5144_CR36","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.echo.2014.11.003","volume":"28","author":"JU Voigt","year":"2015","unstructured":"Voigt JU, Pedrizzetti G, Lysyansky P, Marwick TH, Houle H, Baumann R, et al. Definitions for a common standard for 2D speckle tracking echocardiography: consensus document of the EACVI\/ASE\/Industry Task Force to standardize deformation imaging. J Am Soc Echocardiogr. 2015;28(2):183\u201393. https:\/\/doi.org\/10.1016\/j.echo.2014.11.003.","journal-title":"J Am Soc Echocardiogr"},{"issue":"23 Suppl","key":"5144_CR37","first-page":"5823 s","volume":"55","author":"YE Erdi","year":"1995","unstructured":"Erdi YE, Wessels BW, Loew MH, Erdi AK. Threshold estimation in single photon emission computed tomography and planar imaging for clinical radioimmunotherapy. Cancer Res. 1995;55(23 Suppl):5823 s\u20136 s.","journal-title":"Cancer Res"},{"issue":"1","key":"5144_CR38","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s13550-017-0262-7","volume":"7","author":"J Gustafsson","year":"2017","unstructured":"Gustafsson J, Sundlov A, Sjogreen GK. SPECT image segmentation for estimation of tumour volume and activity concentration in (177)Lu-DOTATATE radionuclide therapy. EJNMMI Res. 2017;7(1):18. https:\/\/doi.org\/10.1186\/s13550-017-0262-7.","journal-title":"EJNMMI Res"},{"issue":"12","key":"5144_CR39","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1093\/ehjci\/jex244","volume":"18","author":"M Galderisi","year":"2017","unstructured":"Galderisi M, Cosyns B, Edvardsen T, Cardim N, Delgado V, Di Salvo G, et al. Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2017;18(12):1301\u201310. https:\/\/doi.org\/10.1093\/ehjci\/jex244.","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"19","key":"5144_CR40","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1136\/heartjnl-2012-302353","volume":"98","author":"D Phelan","year":"2012","unstructured":"Phelan D, Collier P, Thavendiranathan P, Popovic ZB, Hanna M, Plana JC, et al. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart. 2012;98(19):1442\u20138. https:\/\/doi.org\/10.1136\/heartjnl-2012-302353.","journal-title":"Heart"},{"issue":"1","key":"5144_CR41","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.jcmg.2017.02.012","volume":"11","author":"A Martinez-Naharro","year":"2018","unstructured":"Martinez-Naharro A, Abdel-Gadir A, Treibel TA, Zumbo G, Knight DS, Rosmini S, et al. CMR-verified regression of cardiac AL amyloid after chemotherapy. JACC Cardiovasc Imaging. 2018;11(1):152\u20134. https:\/\/doi.org\/10.1016\/j.jcmg.2017.02.012.","journal-title":"JACC Cardiovasc Imaging"},{"key":"5144_CR42","doi-asserted-by":"crossref","unstructured":"Richards AM. Variability of NT-proBNP levels in heart failure: implications for clinical application. Heart. 2007;899\u2013900.","DOI":"10.1136\/hrt.2006.110643"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-020-05144-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-020-05144-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-020-05144-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T09:15:19Z","timestamp":1620724519000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-020-05144-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,26]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["5144"],"URL":"https:\/\/doi.org\/10.1007\/s00259-020-05144-8","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,12,26]]},"assertion":[{"value":"9 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors Pilebro, Lindqvist, and Sundstr\u00f6m have a consultancy agreement with Pfizer. The author Suhr has consultancy agreements with Prothema, Akcea, and Intellia. All other authors have reported that they have no relationships to disclose that are relevant to the contents of this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the central ethical review board at Ume\u00e5 University (Dnr: 06-084M, 2013-407-31M). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed written consent was obtained from each patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}